Retina Synthesis

We discuss the treatment results of high dose aflibercept in the eyes in the most severe quartile of diabetic macular edema with Dr. Roger Goldberg of Walnut Creek, California.

We discuss the use of an IL-6 inhibitor in the treatment of uveitis macular edema with Dr. Sumit Sharma of the Cole Eye Institute, Cleveland Clinic.

We discuss the baseline characteristics of eyes in the HD Aflibercept Phase III clinical trial and examine their ability for extended dosing with Dr. Eric Schneider of Tennessee Retina, Nashville, TN.

We discuss the unique results of the Annexon geographic atrophy Phase I clinical trial with Dr. Roger Goldberg of Bay Area Retina Associates, Walnut Creek, California

We review the latest diagnostic and therapeutic approaches for retinoblastoma with Dr. Jesse Berry, Associate Professor of Ophthalmology, Children's Hospital Los Angeles.

We discuss the feasibility of using home OCT vs. a treat and extend approach in a clinical trial of faricimab in neovascular AMD with Dr. Kevin Blinder of the Retina Institute in Saint Louis, Mo and Profesor of Ophthalmology at Washington University School of Medicine.

We discuss the characteristics of eyes with the best visual outcomes in the Davio trial of TKI EY-1901 with Dr. Philip Storey of the Austin Retina Associates, Austin, Texas.

We discuss a post-hoc study comparing the efficacy of Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol) with Paul Hahn, MD, PhD, of NJ Retina.

We discuss a comparative trial of preventive therapy for non-proliferative retinopathy vs. ad hoc treatment of disease complications with Dr. Hani Salehi-Had of Retina Associates of Southern California, Huntington Beach, California.

We discuss the latest information on phase 2 trials of gene therapy for x-linked retinitis pigmentosa with Dr. Nadia Waheed, Chief Medical Officer of Beacon Therapeutics and Associate Professor of Ophthalmology at the New England Eye Center, Tufts University School of Medicine.

We discuss the use of optogenetics for the treatment of inherited retinal degenerations with Dr. Jose Sahel, Chairman and Distinguished Professor of Ophthalmology at the University of Pittsburgh School of Medicine.

We discuss the importance of intensive therapy of DME, when using aflibercept for DME, as suggested by a review of real world cases from the Vestrum  data base, with Dr. Ferhina Ali, Assistant Professor of Ophthalmology, New York Medical College

We discuss the use of a topical agent for the treatment of diabetic macular edema with Dr. Arshad Khanani, Director of Research, Sierra Eye Associates, Associate Clinical Professor of Ophthalmology, University Nevada School of Medicine, Reno.

We review novel approaches for the treatment of intermediate AMD, with Dr. Barry Kuppermann, Director Gavin Herbert Eye Institute, Chairman Department of Ophthalmology, University of California Irvine, Steinert Endowed Chair.

 In our latest update, we discuss safety issues associated with retinal gene therapy with Professor Glenn Yiu of the University of California School of Medicine.

We discuss the use of a novel oral agent for the treatment of diabetic retinopathy with David R. Lally, MD, Director of Research, New England Retina Consultants, Springfield, MA

We discuss intravitreal gene therapy with a new agent, 4D-150 with Veeral Sheth, MD, MBA  Assistant Clinical Professor of Ophthalmology University of Illinois at Chicago.

We discuss the use of optogenetics in the treatment of retinal degenerations with Dr. Michael Singer, Adjunct Professor of Ophthalmology, University of Texas Health Science Center, San Antonio.

We discuss retinal drying in diabetic macular edema using the Iluvien implant with Dr. Michael Singer, Adjunct Professor, University of Texas Health Science Center, San Antonio.

We discuss the use of blockade of VEGF C and D in the treatment of neovascular AMD with Dr. Dante Pieramici, California Retina Research Foundation, California Retina Consultants.